Management ChangeSep 11, 2026, 04:17 PM
Skye Bioscience CFO Resigns; Nasdaq Bid Price Compliance Regained
AI Summary
Skye Bioscience, Inc. announced the resignation of its Chief Financial Officer, John P. Sharp. Punit Dhillon, the current President and CEO, has been appointed as the interim principal financial and accounting officer. In other news, the company has regained compliance with Nasdaq's minimum bid price requirement, having maintained a closing bid price of at least $1.00 for ten consecutive business days. The company also provided an update on its proposed acquisition of Redx Pharma Limited.
Key Highlights
- John P. Sharp resigned as Chief Financial Officer and principal financial and accounting officer.
- Punit Dhillon, President and CEO, appointed as interim principal financial and accounting officer.
- Skye Bioscience regained compliance with Nasdaq minimum bid price requirement ($1.00 closing bid price for 10 consecutive days).
- Company is proceeding with the proposed acquisition of Redx Pharma Limited.
Price Impact
More from SKYE